6 generic drugs through consistent evaluation from Nanjing Zhengda Tianqing, Shi Pharmaceutical Group...

On August 18, the official website of the State Drug Administration showed that there were six generic drugs evaluated consistently, including Thershuvastatin calcium tablets in Zhengtianqing, Nanjing, Montaigne (15th), Changao Pharmaceuticals' calcium hydroxybenzene tablets (first), Akihito (Liaoning) Pharmaceuticals' Losolofen sodium tablets (2nd) and Stonycin Group's Kramycin tablets (5th), and Gremesin tablets (5th).
, kramycin tablets belong to the third batch of harvesting varieties.
the following selected some varieties for a brief introduction: Ruishuvastatin calcium tablets Ruishuvastatin calcium tablets is a high blood lipid treatment drug, Nanjing Zhengtianqing 10mg specification as early as December 2017 through a consistent evaluation, it is speculated that the evaluation specification should be 5mg.
Ruishuvastatin calcium tablets belong to the alliance area with the volume of procurement varieties, the selected manufacturers are Beijing New, Hanyu Pharmaceuticals and Nanjing Zhengda Qing.
, Jingxin, Hanyu pharmaceutical selected specifications for 10 and 5mg specifications, Nanjing Zhengtian Qing for 5mg specifications.
, the number of calcium lysophates evaluated by consistent evaluation has reached 11, including 10 tablets and 1 capsule.
Glimelue dispersion tablet Gremethal is a medium- and long-acting sulfonylurea antidiabetic drug that stimulates islet β cells to secrete insulin, which in turn lowers blood sugar levels in people with type 2 diabetes.
Sanofi, a former research manufacturer, was originally approved in the Netherlands in 1995.
the domestic development of gremethal dosage forms have tablets, mouth collapse tablets, capsules, dispersion tablets and drop pills, of which, tablets have been included in the second batch of national collection, the current domestic evaluation manufacturers reached 9.
2017 domestic sales of about 970 million yuan, according to the company's statistics.
Pharmaceutical Group is the first manufacturer to pass the Glimexacin dispersion tablet consistency evaluation.
2020Q1 financial results show that its gremethyl dispersion tablets and metformin hydrochloride tablets slow release tablets in the first quarter sales revenue of 0.88 billion yuan, an increase of 56.3% YoY.
kramycin tablets Clariamycin tablets are suitable for infections caused by kramycin-sensitive bacteria: rhinitis infections, lower respiratory tract infections, etc., but also for Legionella infections or in the treatment of bird branch bacillus infections, Helicobacter pyrobacteria infections in combined with other drugs.
data show that kramycin sales in the country's urban sample public hospitals in 2019 was 819 million yuan.
there are currently 4 enterprises through kramycin consistency evaluation, of which, The East Sunshine tablets and slow release tablets have passed the consistent evaluation.
Group submitted a consistent evaluation application for two receiving numbers of kramycin tablets (CYHB1950533 and CYHB1950534), but only the acceptance number CYHB1950534 passed the consistency evaluation.
kramycin tablets for the third batch of collecting varieties, Stone Pharmaceutical Group this time through a consistent evaluation, and the above four enterprises and the original pharmaceutical company Abbott to compete.
in accordance with the rules, qualified manufacturers to reach 6 varieties, the maximum number of finalists will be 4.
In the third batch of national collections to be held this week, Stone Pharmaceuticals has selected a number of varieties, including ibuprofen particles, metformin hydrochloride tablets/tablets, catapololi tablets, hydrochloric acid macacoon tablets, Monrust sodium chewing tablets, celexib capsules, tigrillo tablets and kramycin tablets.
we'll see how the final bid from Stone Pharmaceuticals companies turns out!